TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29084080

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 31

Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 31
Study: 25986447

Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg daily)
Number of subjects: 253
Study: 24867069

Group type: EXPERIMENTAL
Intervention: Arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplementation (twice per day for 16 weeks)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control drink (twice per day for 16 weeks)
Number of subjects: 270
Study: 22942114

Group type: EXPERIMENTAL
Intervention: HIFU treatment at 47 J/cm² (141 J/cm² total)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIFU treatment at 59 J/cm² (177 J/cm² total)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control (0 J/cm², no energy applied)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIFU treatment (all energy levels)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 19127427

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1387

Group type: COMPARATOR
Intervention: CC with two doses rFSH
Number of subjects: 1387

Group type: COMPARATOR
Intervention: Continuous rFSH
Number of subjects: 1387
Study: 17202560

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Methylphenidate (54 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 15609471

Group type: EXPERIMENTAL
Intervention: High-dose interleukin (IL)-2 (Proleukin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy with IL-2 and interferon-alfa (biochemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase III multicenter studies
Number of subjects: 0
Study: 12562068

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) training, 30 minutes daily for 10 treatments
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional training, 30 minutes daily for 10 treatments
Number of subjects: 50
Study: 11475729

Group type: EXPERIMENTAL
Intervention: Prostatitis decoction
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Capsule of Prostatitis decoction
Number of subjects: 561

Group type: COMPARATOR
Intervention: Qianliekang tablets (Control)
Number of subjects: 561
Study: 8580795

Group type: EXPERIMENTAL
Intervention: 400 mg/m2/day etoposide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 600 mg/m2/day etoposide
Number of subjects: 50

Group type: COMPARATOR
Intervention: 200 mg/m2/day etoposide (control group)
Number of subjects: 50
Study: 2526769

Group type: EXPERIMENTAL
Intervention: Nicotinamide 3 g/day for 9 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo for 9 months
Number of subjects: 26
Study: 359494

Group type: EXPERIMENTAL
Intervention: Cetiedil (100 mg, t.i.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg, t.i.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Orciprenaline (20 mg, t.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (100 mg Lactose, t.i.d.)
Number of subjects: 40
Study: 31923778

Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise program
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lumbar muscle strengthening exercise program
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both exercise programs
Number of subjects: 70
Study: 31905644

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for eight weeks with a commercially available respiratory muscle trainer (Threshold IMT), 80 inhalations (twice per day, five days per week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular preseason soccer training including incremental endurance training (IET)
Number of subjects: 16
Study: 28346151

Group type: EXPERIMENTAL
Intervention: Short sleep (<7 hours)
Number of subjects: 10086

Group type: EXPERIMENTAL
Intervention: Long sleep (>9 hours)
Number of subjects: 10086

Group type: EXPERIMENTAL
Intervention: Higher PA (higher accelerometer counts and ≥20 minutes of accumulated MVPA)
Number of subjects: 10086
Study: 26092388

Group type: EXPERIMENTAL
Intervention: Clinical-guideline-recommended supervised physiotherapy exercise sessions (10 sessions) integrated with six (once per week) SIT sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical-guideline-recommended supervised physiotherapy exercise sessions (10) only
Number of subjects: 100
Study: 23220080

Group type: EXPERIMENTAL
Intervention: Niacinamide-containing formulations applied twice daily for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle-control treated sites
Number of subjects: 20
Study: 21613278

Group type: EXPERIMENTAL
Intervention: Subcutaneous cervical plexus block
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intermediate cervical plexus block
Number of subjects: 44
Study: 19361800

Group type: EXPERIMENTAL
Intervention: Interpersonal support and digital vaginal palpation (DVP) as part of pelvic floor muscle exercise (PFME) training
Number of subjects: 99

Group type: COMPARATOR
Intervention: PFME with a printed handout instruction
Number of subjects: 99
Study: 16780598

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA)
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1574
Study: 15271098

Group type: EXPERIMENTAL
Intervention: Glucose challenge with an interval of 30 min
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucose challenge with an interval of 60 min
Number of subjects: 29
Study: 11216430

Group type: EXPERIMENTAL
Intervention: Minilaparoscopy (ML)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 92
Study: 9264494

Group type: EXPERIMENTAL
Intervention: Verapamil 240 to 480 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril 10 to 40 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group of normotensive subjects
Number of subjects: 20
Study: 8283942

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 607

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 607
Study: 3107444

Group type: EXPERIMENTAL
Intervention: Negative pressure ventilator for 3 to 6 hours daily for 3 consecutive days (Group B)
Number of subjects: 15
Study: 29978307

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 60
Study: 27320562

Group type: EXPERIMENTAL
Intervention: PCA fentanyl with IV parecoxib 40 mg
Number of subjects: 101
Study: 25010921

Group type: EXPERIMENTAL
Intervention: Navigation grid (NG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Verbal instructions alone (Control)
Number of subjects: 30
Study: 22651702

Group type: EXPERIMENTAL
Intervention: True LBBB morphology
Number of subjects: 111

Group type: COMPARATOR
Intervention: False LBBB morphology
Number of subjects: 111

Group type: COMPARATOR
Intervention: Bisoprolol dose <5 mg
Number of subjects: 111
Study: 20646286

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural programme
Number of subjects: 125
Study: 18586125

Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy (PT) training for 12 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy (PT) training + electric muscle stimulation (EMS) for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (PT only)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (PT + EMS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (PT and PT + EMS)
Number of subjects: 38
Study: 16842528

Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (n=35)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Myeloablative conditioning (n=70)
Number of subjects: 105
Study: 12514398

Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 19

Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 19
Study: 10971103

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8843172

Group type: EXPERIMENTAL
Intervention: Gliclazide (240 mg orally)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1632534

Group type: EXPERIMENTAL
Intervention: Combined therapy (ketorolac 60 mg IV and bupivacaine 0.5% 30 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine (0.5% 30 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketorolac (60 mg)
Number of subjects: 60
Study: 6317858

Group type: EXPERIMENTAL
Intervention: VLI contraceptive sponge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diaphragm with spermicide
Number of subjects: 0
Study: 30753540

Group type: EXPERIMENTAL
Intervention: POIBA intervention (9-session classroom program, 6 weekly physical education sessions, out-of-school physical activity, family workshop)
Number of subjects: 3073

Group type: COMPARATOR
Intervention: Comparison group (CG)
Number of subjects: 3073

Group type: EXPERIMENTAL
Intervention: POIBA intervention
Number of subjects: 3073
Study: 29874959

Group type: EXPERIMENTAL
Intervention: Detailed accounts (high detail)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vague accounts (low detail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional accounts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-emotional accounts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reliability measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personality measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Political orientation measures
Number of subjects: 0
Study: 27048410

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy for 8 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Medication group (budesonide nasal spray with cetirizine tablets for 8 weeks)
Number of subjects: 76
Study: 25282707

Group type: EXPERIMENTAL
Intervention: TQ intervals analysis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CAFW analysis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: RPI for paroxysmal AF cases
Number of subjects: 62
Study: 22704059

Group type: EXPERIMENTAL
Intervention: Participants with a parental history of depression
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study: 20682573

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 220

Group type: COMPARATOR
Intervention: 1% plain subcutaneous lidocaine
Number of subjects: 220
Study: 17717933

Group type: EXPERIMENTAL
Intervention: Qishen Yiqi Drop Pill
Number of subjects: 0
Study: 15640488

Group type: EXPERIMENTAL
Intervention: Green tea (6 g green tea solids)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Black tea (6 g black tea solids)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (360 mg caffeine)
Number of subjects: 17
Study: 12360170

Group type: EXPERIMENTAL
Intervention: Exercise training (5 sessions of 45 minutes per week for 2 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 24
Study: 10418844

Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tone-evoked P300 response
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response in mild TBI
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tone-evoked P300 response in mild TBI
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response in severe TBI
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tone-evoked P300 response in severe TBI
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response in moderate TBI
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tone-evoked P300 response in moderate TBI
Number of subjects: 28
Study: 7560667

Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate (100 mg administered intravenously)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Aspirin (oral challenge)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 53
Study: 2393271

Group type: EXPERIMENTAL
Intervention: Cefazolin (mean, 178.6 mg/h)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cefuroxime (mean, 330.0 mg/h)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 29
Study: 7015262

Group type: EXPERIMENTAL
Intervention: One-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ten-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Short-term therapy (one or four days of antibiotics)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy (ten-day regimen)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Short-term therapy (all children in both studies)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy (all children in both studies)
Number of subjects: 80
Study: 30625184

Group type: EXPERIMENTAL
Intervention: Therapy dog exposure (15 min)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 86
Study: 29995456

Group type: EXPERIMENTAL
Intervention: 21 days of bed rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Upstream regulator analysis of MEF2 family
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MicroRNA expression analysis
Number of subjects: 12
Study: 27687468

Group type: EXPERIMENTAL
Intervention: nerve stimulator-guided pudendal nerve block (PNB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: general anesthesia (GA)
Number of subjects: 57
Study: 24908551

Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir (switch group)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor with emtricitabine and tenofovir (no-switch group)
Number of subjects: 433
Study: 20977611

Group type: EXPERIMENTAL
Intervention: Immediate implants with immediate loading (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional loading after 3 months (group B)
Number of subjects: 60
Study: 19441871

Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir DF 200 mg/300 mg once daily plus lopinavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir DF 200 mg/300 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir DF in combination with various boosted PIs
Number of subjects: 0
Study: 17497471

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly (n = 47)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly (n = 44)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg per day (n = 36)
Number of subjects: 127
Study: 15515441

Group type: EXPERIMENTAL
Intervention: Communication training program for nursing assistants
Number of subjects: 0
Study: 11570731

Group type: EXPERIMENTAL
Intervention: Manual lifting task
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lying on the back for 8 hours
Number of subjects: 32
Study: 11246837

Group type: EXPERIMENTAL
Intervention: Educational group (group E) with antihypertensive drug treatment and patient education
Number of subjects: 169

Group type: COMPARATOR
Intervention: Routine group (group R) with antihypertensive drug treatment alone
Number of subjects: 169
Study: 7843814

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g administered intravenously within 1 h before surgery and a second dose 3-4 days postoperatively.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis).
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ceftriaxone treatment.
Number of subjects: 101
Study: 3322826

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 4081

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 4081
Study: 30035580

Group type: EXPERIMENTAL
Intervention: MCQ/MCQ
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MCQ/MCQ-A
Number of subjects: 84
Study: 28628810

Group type: EXPERIMENTAL
Intervention: GH administration (starting dose 2μg/kg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 25637651

Group type: EXPERIMENTAL
Intervention: Exposed condition (additional irrelevant colour cue shown during presentation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unexposed condition (no additional colour cue)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exposed patients (additional irrelevant colour cue shown during presentation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unexposed patients (no additional colour cue)
Number of subjects: 24
Study: 23648162

Group type: EXPERIMENTAL
Intervention: Low VT ventilation group (VT set on 6-7 ml/kg, high pressure alarm threshold adjusted to 60 cm H2O)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional VT group (VT set at 8-12 ml/kg, high pressure alarm threshold at 40 cm H2O)
Number of subjects: 40
Study: 21682929

Group type: EXPERIMENTAL
Intervention: Computerised working memory training (25 sessions, 35 minutes each)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Computerised working memory training
Number of subjects: 440
Study: 19107089

Group type: EXPERIMENTAL
Intervention: Back School program (4 weekly classes of 60 minutes)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 70
Study: 15005771

Group type: EXPERIMENTAL
Intervention: Peanut flour in mashed potatoes (2.7, 8.9, or 26.8 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Hazelnut flour in oatmeal porridge (74, 247, or 742 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo recipes
Number of subjects: 81
Study: 10201789

Group type: EXPERIMENTAL
Intervention: Total fundic wrap
Number of subjects: 24

Group type: COMPARATOR
Intervention: Posterior partial (Toupet) fundoplication
Number of subjects: 24
Study: 8642803

Group type: EXPERIMENTAL
Intervention: Rilmenidine (RIL) 1 mg o.d. or b.i.d.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Captopril (CAP) 25 or 50 mg b.i.d.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rilmenidine (RIL) and Captopril (CAP)
Number of subjects: 51
Study: 2158355

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg once daily for 3 consecutive weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 465434

Group type: EXPERIMENTAL
Intervention: B‐complex vitamins (4 mg riboflavin and 10 mg pyridoxine) daily for 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of gentian violet
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vitamin supplements
Number of subjects: 0
Study: 29635953

Group type: EXPERIMENTAL
Intervention: Wizmi non-invasive glucose measurements
Number of subjects: 32
Study: 26790204

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Catgut embedding
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: PDS embedding
Number of subjects: 279
Study: 24810282

Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement education program (25-min video, 20-min patient-centered interview, 10-min telephone follow-up)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement education program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 22743378

Group type: EXPERIMENTAL
Intervention: Ketofol (ketamine/propofol admixture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 0
Study: 19201317

Group type: EXPERIMENTAL
Intervention: Highly filled light-cured sealant (HFLCS) - Pro Seal, Reliance Orthodontic Products, Itasca, Ill
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional composite resin (control group)
Number of subjects: 30
Study: 17431740

Group type: EXPERIMENTAL
Intervention: Randomized treatment (specific intervention details not available)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 31
Study: 15333722

Group type: EXPERIMENTAL
Intervention: Olive oil with low phenolic content (LPC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olive oil with moderate phenolic content (MPC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olive oil with high phenolic content (HPC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olive oils (LPC, MPC, HPC)
Number of subjects: 12
Study: 11438268

Group type: EXPERIMENTAL
Intervention: Formal instruction on PE skills at the beginning of the clerkship (Group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Instruction on PE skills at the midpoint of the clerkship (Group B)
Number of subjects: 49
Study: 9736546

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose on day 1, then 200 mg once daily)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg twice daily)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 419

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 419
Study: 8293400

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 249

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (crossover)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Tamoxifen (crossover)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 249
Study: 2620055

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dinoprostone pessary (3 mg)
Number of subjects: 0
Study: 29513609

Group type: EXPERIMENTAL
Intervention: REDCap assessments
Number of subjects: 36
Study: 28097941

Group type: EXPERIMENTAL
Intervention: Telemedicine support (TMS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 72
Study: 25522347

Group type: EXPERIMENTAL
Intervention: Weight stigma manipulation
Number of subjects: 110
Study: 24086602

Group type: EXPERIMENTAL
Intervention: Momentary Positive Affect (PA) persistence
Number of subjects: 540